During the EuroPCR 2017, I have presented theOne year clinical outcome of percutaneous treatment with Sirolimus eluting balloons: Results from Nanolute prospective registry.
Prospective, Multi‐center clinical registry real world, all comers patients at various indian Interventional Cardiology Sites. Clinical Follow-up at 1,6 and 12 Months.
SCB might constitute a new therapeutic option, considering the overall complexity of modern-era interventional cardiology.
The results of this registry, performed in indian patients, are encouraging, but deserve more complete clinical assessment in broader patients populations.
A synergistic DCB use with new-generation DES is intriguing
Here’s the presentation of the meeting4 NANOLUTE' presentation